FLUTICASONE FUROATE 0.0275%w/w IP + AZELASTINE HYDROCHLORIDE 0.140%w/w IP + BENZ...

An intranasal formulation for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis in adults and adolescents when monotherapy is insufficient. (Bull., 2014) Effectively reduces inflammation in the nasal passages, and relieves nasal congestion caused by allergies. An ideal treatment option for seasonal allergic rhinitis (SAR). (Prenner, 2016) Quickly alleviates symptoms like itching, sneezing, and runny nose, and reduces inflammation and congestion associated with allergic rhinitis. Blocks the action of histamine, which is a key mediator in allergic reactions, helping to alleviate symptoms like sneezing, itching, and runny nose. Provides faster and more complete symptom control compared to first-line therapies in seasonal allergic rhinitis patients. (Eli Meltzer, 2013) Significantly improves nasal symptoms more than either individual agent alone, offering both immediate and sustained relief for moderate-to-severe seasonal allergic rhinitis. (Frank C Hampel, 2010) Offers substantial therapeutic benefits for patients with seasonal allergic rhinitis compared to monotherapy. (Paul H Ratner, 2008) More effective than each agent alone for treating moderate to severe nasal symptoms of seasonal allergic rhinitis. (Paul H Ratner, 2008) Provides relief from both nasal and ocular symptoms twice as effectively as using either fluticasone or azelastine alone. (Bull., 2014) Alleviates nasal symptoms up to 6 days faster than fluticasone in allergic rhinitis individuals. (Bull., 2014) Delivers two-fold better relief for nasal and ocular symptoms than monotherapy with azelastine hydrochloride and fluticasone propionate. (Pongsakorn Tantilipikorn, 2024)